Peter Diamandis
About Peter Diamandis
Peter H. Diamandis, M.D., age 63 as of October 30, 2025, has served on Celularity’s board since the July 2021 business combination; he previously co-founded Legacy Celularity and was its Vice Chairman from 2016. He holds degrees in Molecular Engineering and Aerospace Engineering from MIT and an M.D. from Harvard Medical School, and is widely recognized for technology and innovation leadership through XPRIZE and Singularity University. He is independent under Nasdaq/SEC rules and stands for re‑election as a Class I director at the 2025 annual meeting.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Legacy Celularity | Vice Chairman; co‑founder | 2016–2021 | Helped build pre‑merger governance and strategic direction |
| Human Longevity, Inc. | Vice Chairman & co‑Founder | Ongoing | Longevity/biotech expertise; external network |
| XPRIZE Foundation | Founder & Executive Chairman | Ongoing | Large‑scale incentive competitions; innovation governance |
| Singularity University | Executive Founder | Founded 2008 | Executive education on exponential tech |
External Roles
| Organization | Type | Role | Notes |
|---|---|---|---|
| Vaxxinity | Public company | Director | Current board service |
| DPCM Capital | Public company | Director | Current board service |
| SWAG III (Nasdaq: SWAG) | Public company | Director | Current board service |
Board Governance
- Committee assignments (2024): Compensation Committee member; Nominating & Corporate Governance Committee member (and currently Chair). Audit Committee: not a member.
- Independence: Board determined all directors except CEO Robert Hariri are independent under Nasdaq and SEC rules; Diamandis is independent.
- Board/class structure: Class I (Diamandis, Parks, Ling) terms expire at the 2025 annual meeting.
- Attendance: Board met 7 times in 2024; each director attended ≥75% of board and applicable committee meetings; Annual Meeting attendance by six of nine directors. Committee meetings in 2024: Audit 7, Compensation 2, Nominating 3.
| Committee | Assignment | Chair | 2024 Meetings |
|---|---|---|---|
| Audit | Not a member | Vincent LeVien | 7 |
| Compensation | Member | Diane Parks | 2 |
| Nominating & Corporate Governance | Member; currently Chair | Diamandis | 3 |
Fixed Compensation
| Year | Fees Earned/Paid in Cash ($) | Stock Awards ($) | Option Awards ($) | Total ($) |
|---|---|---|---|---|
| 2024 | 53,000 | 150,001 | 150,000 | 353,001 |
| Policy Component (Non‑Employee Director) | Amount/Structure |
|---|---|
| Annual cash retainer (2022 policy) | $45,000 |
| Committee membership retainers | Audit $10,000; Compensation $8,000; Nominating $5,000 |
| Committee chair retainers | Audit $20,000; Compensation $16,000; Nominating $10,000 |
| Annual equity award | $300,000; 50% options / 50% RSUs; granted at annual meeting |
| Initial equity grant (on joining board) | $300,000 of options; vests ratably over 3 years |
| Non‑employee director annual cap | $750,000 (or $1,000,000 in first year on board) |
Performance Compensation
- Equity structure and recent grants: Annual equity = $300,000 split 50/50 options and RSUs; at the 2024 annual meeting, each director (including Diamandis) received options to acquire 84,746 shares and 67,416 RSUs. Initial director option grant ($300,000) vests ratably over three years. No performance‑conditioned metrics are disclosed for director equity (grants are time‑based).
| Metric | Detail |
|---|---|
| Annual equity grant value ($) | 300,000 |
| 2024 options granted (#) | 84,746 |
| 2024 RSUs granted (#) | 67,416 |
| Initial options grant value ($) | 300,000 |
| Initial options vesting | Ratably over 3 years |
| Options outstanding (12/31/2024) | 416,459 |
| Unvested RSUs (12/31/2024) | 67,416 |
| RSUs vesting timeline | 67,416 will vest within 60 days of Oct 30, 2025 |
Equity award timing policy: Company avoids option grants near material disclosures; bars grant timing based on MNPI; derivative transactions and short sales prohibited; options not granted within restricted windows around filings.
Other Directorships & Interlocks
| Company | Relationship | Potential Interlock/Conflict Considerations |
|---|---|---|
| Human Longevity, Inc. | Diamandis Vice Chair & co‑Founder | CEO Hariri also co‑founded HLI; shared external affiliation may create information/network interlock outside CELU; board affirms director independence despite associations. |
| Vaxxinity; DPCM Capital; SWAG III | Public company boards | No CELU‑disclosed transactions with these entities; monitor for future related‑party exposure. |
Expertise & Qualifications
- Technology and life‑sciences innovator: Founder/leader at XPRIZE and Singularity University; deep exposure to exponential tech and innovation governance.
- Biotech/longevity domain knowledge: Vice Chairman/co‑Founder at Human Longevity; operational/management experience relevant to CELU’s sector.
- Education: MIT (Molecular Engineering, Aerospace Engineering); Harvard Medical School (M.D.).
Equity Ownership
| Holder | Total Beneficial Ownership (Shares) | % of Outstanding | Direct Shares | Options (Exercisable/within 60 days) | RSUs (vesting within 60 days of 10/30/2025) |
|---|---|---|---|---|---|
| Peter H. Diamandis, M.D. | 618,182 | 2.2% | 134,307 | 416,459 | 67,416 |
Pledging/hedging: Company policy prohibits short sales and derivative transactions; pledging requires advance Audit Committee approval. No pledging or hedging by Diamandis is disclosed.
Governance Assessment
- Strengths: Independent director; Chair of Nominating & Corporate Governance; active Compensation Committee member; ≥75% meeting attendance; material personal share/option/RSU holdings align incentives.
- Compensation mix: Balanced cash plus equity; standardized annual equity ($300k) split evenly between options and RSUs; clear vesting for initial grants; aggregate annual director pay subject to caps.
- Policies: Robust insider trading restrictions; structured process for related‑party transactions with mandatory recusal; public committee charters and annual reviews.
- Potential RED FLAGS to monitor:
- Shared external affiliation with CEO at Human Longevity, Inc. (interlock risk); board has assessed independence but investors may monitor for related‑party transactions or information flows.
- Historical role as Legacy Celularity Vice Chairman (pre‑merger) may warrant continued scrutiny of independence in practice, though currently independent under Nasdaq/SEC.
- Not disclosed: Director‑specific stock ownership guidelines, strike prices/expirations for director options, performance metrics tied to director compensation, say‑on‑pay vote outcomes.